FDA "Drug Watch" Website To Include Three Categories Of Safety Information
This article was originally published in The Pink Sheet Daily
Executive Summary
The site will reflect information about serious adverse events, patient selection and monitoring, and risk minimization procedures, an FDA draft guidance states. Manufacturers will be notified "shortly before" information about a drug is first posted; agency suggests the site's information will not be used for promotional purposes.